Hims & Hers Health (HIMS): The FTC Suit Didn't Break It, But Neither Has The Bull Case

Hims & Hers stock is up nearly 14% over the past five sessions. The rally follows two events that, on the surface, should have sent investors running in opposite directions: the FTC filed a federal lawsuit alleging the company shared patients' sensitive health data with Meta and Snap and charged customers before they spoke with a provider, and the company launched a doctor-led AI-native care experience for its women's weight-loss program.

The market interpreted the lawsuit as survivable and the AI launch as visionary. The stock responded by surging. But the question isn't whether either headline changed the bull case. The question is whether the bull case can survive the numbers.

Hims & Hers trades at a forward P/E of 39.7x. Revenue growth over the trailing twelve months is 32.8%. In a growth-at-a-reasonable-price framework, the forward multiple should ideally sit at or below the growth rate to leave a margin of safety. Here, the multiple sits above the growth rate, and the stock's PEG ratio (price-to-earnings-growth) is 5.2x — meaning investors are paying more than five cents for every dollar of expected growth.

That is not a battered-growth setup. It is a richly valued one, even if the stock is down 38% over the trailing twelve months from its high of $65.30.

The Valuation Gate

More concerning than the multiple is what sits beneath it. In the first quarter of 2026 — the company's most recent full reporting period — Hims & Hers swung from a $49.5 million profit to a $92 million net loss. Gross margin collapsed to 65%, down from 73% a year earlier. Free cash flow growth turned negative at minus 74%. The company reported earnings of minus $0.40 per share against consensus expecting a small profit.

Management framed the hit as deliberate. CFO Yemi Okupe acknowledged "near-term financial noise" as the company pivots from compounded GLP-1 drugs to branded medications from Novo Nordisk and Eli Lilly. $33 million in restructuring costs, largely write-downs of the old compounding supply chain, weighed on the quarter. But the underlying economics also deteriorated: monthly revenue per average subscriber fell from $85 to $80.

The Moat Under Stress

A contrarian thesis requires the moat to survive the selloff. Hims & Hers' moat is its brand trust and its 2.6 million-subscriber base, which grew 9% year over year. The AI launch — a rebuilt Hers app with embedded AI coaching, clinician escalation, and a free smart scale — is squarely aimed at protecting that moat by improving retention in its weight-loss segment.

But the FTC suit attacks the moat directly. The complaint, filed July 29th and jointly brought by the FTC, California, and Utah, alleges Hims & Hers shared patients' medical conditions with advertising platforms through tracking technologies, charged customers before they received a provider consultation, and made it deliberately difficult to cancel subscriptions. The company has described the lawsuit as "baseless" and vowed to defend itself vigorously.

The FTC investigation ran for nearly three years before the complaint was filed. That is not a headline-grabbing stunt; it is a sustained regulatory probe. The worst-case outcome — forced changes to billing practices, privacy compliance costs, or injunctive relief altering how the company operates — is not priced into the stock. If the market is treating the suit as non-event because the shares rallied, that reflects short-term resilience, not long-term resolution.

What The AI Launch Actually Does

The AI-native care experience announced August 6th is the kind of product move that sounds transformative in a press release and reads as incremental in a competitive context. It embeds AI guidance — backed by clinicians, not standalone chatbots — into the weight-loss journey. Members share goals and medication history, the AI provides coaching, and a smart scale syncs weight data automatically.

The strategic value is retention, not acquisition. AI-powered tracking and lifestyle guidance are becoming table stakes: Noom, WeightWatchers, and other competitors are already embedding similar tools. An industry survey from May 2026 found 49% of consumers who use AI for guidance seek health and wellness advice, making this a demand-backed feature rather than a blue-sky differentiator. Twenty-two percent of women have used a GLP-1 medication, according to KFF data from late 2025, and women require more ongoing coaching and medication management than men — which makes them the right audience to target first.

The AI launch is not a reason to change the bull case. It is a reason to believe the company is fighting for subscriber retention in a market where competition is shifting from drug access to service quality. That's good execution, not a growth inflection.

The Price Action Picture

Technically, the stock is sitting at $31.59, having recovered sharply from a 52-week low of $13.74. The RSI sits at 51 — neutral territory. The MACD is negative at minus 0.56, suggesting underlying momentum remains bearish despite the recent surge. Price is trading just above the 50-day moving average of $31.44 and above the 200-day average of $29.73, meaning the stock has broken above both key trendlines but hasn't yet established a confirmed uptrend. ATR (average true range) of $2.64 signals continued high volatility.

The stock is up 94% over 120 days but down 38% on a rolling annual basis. That tells you this is a deep-rebound setup, not a fresh-bottom setup. The selling that took it from $65 to $14 has been followed by a recovery to roughly mid-range. That is a stock finding a floor, not a stock that has been thrown out with the bathwater.

AInvest's aggregate signal labels Hims & Hers a Hold with a composite analysis rating of 1.44, a fundamental rating of 10, and a liquidity rating of 7.92 — signaling the aggregate model sees solid fundamentals but does not see a clear directional edge at current levels.

Tomorrow Changes Everything

The single most important fact for anyone holding or watching this stock: Q2 2026 earnings are reported after market close tomorrow, August 10. Consensus expects revenue of $690 million to $700 million and an EPS in the range of minus $0.05 to minus $0.10. The company guided for Q2 revenue of $680 million to $700 million, so consensus is essentially pricing in the top end of that range.

What matters isn't whether revenue hits the forecast. What matters is whether gross margin is stabilizing after the Q1 collapse, whether the branded GLP-1 transition is generating the subscriber growth management promised (north of 100,000 new weight-loss subscribers per month), and whether the company's full-year guidance of $2.8 billion to $3 billion in revenue and $275 million to $350 million in adjusted EBITDA still feels credible after the margin shock.

Where The Risk/Reward Stands

The market has arguably baked in the assumption that the FTC suit is manageable and the GLP-1 pivot will pay off. The 14% rally in five days suggests sentiment has moved from "something is wrong" to "the worst is behind us." But the numbers from the last full quarter tell a different story: profitability is gone, margins are compressed, cash flow growth is collapsing, and the company carries $1.82 billion in total debt against $222 million in cash.

The long-term vision — $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, international expansion through Zava and the Eucalyptus acquisition, a vertically integrated peptide supply chain — is real. The subscriber base is growing. The market for GLP-1 weight-loss drugs is expanding. Hims & Hers is one of the few consumer-facing platforms with scale, brand, and clinical infrastructure to capture demand.

But at 40x forward earnings on a company that lost money last quarter and is expected to lose money this one, the stock is pricing in the long-term vision, not the near-term reality. The valuation gap between what the company is earning today and what the market expects it to earn in four years is where the risk lives.

I don't think this is a buying opportunity at current levels. The stock has recovered too much from the lows for the downside to feel protected, and the forward multiple is too rich for the fundamentals to justify conviction entry. If you own the stock, tomorrow's earnings report will tell you whether the margin trajectory justifies holding through the GLP-1 transition. If you're on the sidelines, wait for Q2 results to confirm whether the company is stabilizing before deploying capital.

I would reassess on a pullback below the 200-day moving average of $29.73, which would bring the forward P/E closer to the 35x range and give the growth rate room to catch up to the multiple. Or I'd reassess if Q2 shows gross margin rebounding toward the low 70s and subscriber growth exceeding the 100,000-per-month target management set in March.

The bull case hasn't changed. But neither has the risk profile improved enough to call this an asymmetric setup. Sometimes the right move is to let the earnings do the talking.